ACKR3 and invasive breast carcinoma: Therefore, exploring the role of CXCR7 in BrCa progression is clinically relevant and targeting the CXCR7-EGFR interaction might be a first line of therapy for patients presenting with primary tumors with CXCR7 over expression.